Evidence map›Paper›PMID 41359186›Full record

ReviewLung2025

State of the Art Review: Glucagon-Like Peptide-1 in Obesity-Related Asthma.

Destiny R Gomez, Isaac Swartzman, Angela Linderholm, Bethany P Cummings, Amir A Zeki, Krishna M Sundar, Nicholas J Kenyon

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Lung, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Destiny R GomezUC Davis Lung Center, Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California, Davis School of Medicine, Davis, CA, USA.ORCID http://orcid.org/0000-0002-6757-5621
Isaac SwartzmanDepartment of Internal Medicine, UC Davis School of Medicine, Sacramento, CA, USA.ORCID http://orcid.org/0000-0003-3203-6625
Angela LinderholmUC Davis Lung Center, Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California, Davis School of Medicine, Davis, CA, USA.ORCID http://orcid.org/0000-0002-8561-3089
Bethany P CummingsDepartment of Molecular Biosciences, School of Veterinary Medicine, University of California-Davis, Davis, CA, USA.ORCID http://orcid.org/0000-0002-0610-9870
Amir A ZekiUC Davis Lung Center, Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California, Davis School of Medicine, Davis, CA, USA.ORCID http://orcid.org/0000-0001-8901-588X
Krishna M SundarUC Davis Lung Center, Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California, Davis School of Medicine, Davis, CA, USA.ORCID http://orcid.org/0000-0001-7220-5767
Nicholas J KenyonUC Davis Lung Center, Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California, Davis School of Medicine, Davis, CA, USA. njkenyon@health.ucdavis.edu.

Funding

TRAINING IN COMPARATIVE LUNG BIOLOGY AND MEDICINET32HL007013 · UNIVERSITY OF CALIFORNIA DAVIS · 1985 to 2025
$1.6M
NHLBI NIH HHS T32 HL007013T32 Training Program in Comparative Lung Biology and Medicine #HL007013-46
6 · The paper itself

Abstract

Asthma is a heterogeneous condition characterized by chronic airway inflammation, airway hyperresponsiveness, and mucin hypersecretion. Obesity-related asthma is one phenotype of asthma with significant metabolic dysregulation. A complete understanding of obesity-related asthma remains elusive, but it is most often characterized by the absence of hallmark features of Type-2 (T2) high asthma, such as eosinophilia or elevated exhaled nitric oxide (NO) levels. Patients with obesity-related and T2 low asthma with or without type 2 diabetes mellitus (T2DM) experience worse clinical outcomes, including more severe acute exacerbations. Among the Food and Drug Administration (FDA) approved drug classes for T2DM, there is a growing interest in glucagon-like peptide 1 receptor agonists' (GLP-1RAs) ability to potentially exert effects in the airway. Previous studies found that individuals with T2DM and asthma who were prescribed GLP-1RAs, had decreased asthma exacerbations and improved lung function. However, there remains a gap in understanding GLP-1RAs mechanism of action in the lung and airways to improve pulmonary function. In this review we discuss the potential mechanisms by which GLP-1RAs may impact T2 low asthma and offer a therapeutic option for this highly prevalent disorder.

Indexed as

AsthmaDiabetes Mellitus, Type 2Glucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsLungObesityGlucagon-Like Peptide-1 ReceptorHumansGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsAirway inflammationAsthmaGlucagon-Like peptide-1ObesityWeight loss

Identifiers

PMID41359186
PMCPMC13379408

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.